A detailed history of Bellevue Group Ag transactions in Macrogenics Inc stock. As of the latest transaction made, Bellevue Group Ag holds 9,942,313 shares of MGNX stock, worth $31.7 Million. This represents 0.71% of its overall portfolio holdings.

Number of Shares
9,942,313
Previous 9,965,862 0.24%
Holding current value
$31.7 Million
Previous $147 Million 71.2%
% of portfolio
0.71%
Previous 2.3%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.31 - $18.51 $77,947 - $435,891
-23,549 Reduced 0.24%
9,942,313 $42.3 Million
Q1 2024

May 15, 2024

BUY
$9.77 - $21.47 $122,603 - $269,427
12,549 Added 0.13%
9,965,862 $147 Million
Q4 2023

Feb 14, 2024

BUY
$4.48 - $10.11 $672,000 - $1.52 Million
150,000 Added 1.53%
9,953,313 $95.8 Million
Q3 2023

Nov 14, 2023

BUY
$4.48 - $6.19 $866,432 - $1.2 Million
193,400 Added 2.01%
9,803,313 $45.7 Million
Q1 2023

May 15, 2023

BUY
$4.82 - $7.24 $3.04 Million - $4.56 Million
630,000 Added 7.02%
9,609,913 $68.9 Million
Q4 2022

Feb 14, 2023

BUY
$3.34 - $6.98 $5.53 Million - $11.5 Million
1,654,399 Added 22.58%
8,979,913 $60.3 Million
Q1 2022

May 13, 2022

SELL
$8.12 - $16.9 $10 Million - $20.9 Million
-1,234,948 Reduced 14.43%
7,325,514 $64.5 Million
Q4 2021

Feb 10, 2022

BUY
$15.91 - $21.88 $252,412 - $347,126
15,865 Added 0.19%
8,560,462 $137 Million
Q3 2021

Nov 12, 2021

BUY
$19.74 - $28.7 $23.1 Million - $33.5 Million
1,168,571 Added 15.84%
8,544,597 $179 Million
Q2 2021

Aug 12, 2021

BUY
$20.49 - $35.63 $27.6 Million - $48 Million
1,348,100 Added 22.36%
7,376,026 $198 Million
Q1 2021

May 12, 2021

BUY
$18.99 - $33.2 $2.34 Million - $4.1 Million
123,409 Added 2.09%
6,027,926 $192 Million
Q4 2020

Feb 16, 2021

BUY
$19.41 - $26.0 $12.1 Million - $16.2 Million
622,329 Added 11.78%
5,904,517 $135 Million
Q3 2020

Nov 16, 2020

BUY
$24.69 - $31.6 $6.91 Million - $8.85 Million
280,072 Added 5.6%
5,282,188 $133 Million
Q2 2020

Aug 13, 2020

SELL
$5.2 - $29.12 $5.81 Million - $32.5 Million
-1,117,034 Reduced 18.25%
5,002,116 $140 Million
Q1 2020

May 14, 2020

BUY
$4.28 - $12.11 $1.05 Million - $2.98 Million
245,794 Added 4.18%
6,119,150 $35.6 Million
Q4 2019

Feb 14, 2020

BUY
$7.95 - $12.27 $5.94 Million - $9.18 Million
747,792 Added 14.59%
5,873,356 $63.9 Million
Q3 2019

Nov 14, 2019

BUY
$12.44 - $17.48 $9.08 Million - $12.8 Million
730,300 Added 16.62%
5,125,564 $65.4 Million
Q2 2019

Aug 14, 2019

BUY
$14.51 - $19.71 $52.3 Million - $71.1 Million
3,604,959 Added 456.15%
4,395,264 $74.6 Million
Q1 2019

May 15, 2019

SELL
$11.11 - $25.6 $3.07 Million - $7.08 Million
-276,688 Reduced 25.93%
790,305 $14.2 Million
Q4 2018

Feb 12, 2019

BUY
$11.75 - $21.42 $4.03 Million - $7.34 Million
342,691 Added 47.31%
1,066,993 $13.6 Million
Q3 2018

Nov 13, 2018

BUY
$19.26 - $23.46 $2.45 Million - $2.99 Million
127,389 Added 21.34%
724,302 $15.5 Million
Q2 2018

Aug 07, 2018

BUY
$19.78 - $24.67 $667,812 - $832,908
33,762 Added 6.0%
596,913 $12.3 Million
Q1 2018

May 09, 2018

SELL
$18.89 - $32.46 $23,612 - $40,575
-1,250 Reduced 0.22%
563,151 $14.2 Million
Q4 2017

Feb 14, 2018

BUY
$16.19 - $20.3 $2.12 Million - $2.66 Million
131,102 Added 30.26%
564,401 $10.7 Million
Q3 2017

Nov 13, 2017

BUY
$15.52 - $18.94 $1.81 Million - $2.21 Million
116,881 Added 36.94%
433,299 $8.01 Million
Q2 2017

Aug 14, 2017

BUY
N/A
316,418
316,418 $5.54 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $196M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.